AUS
NZ
UK
CA
USA
IND
Highlights
- Collaborative Innovation: Nona Biosciences partners with Kodiak Sciences to develop novel multi-target antibodies targeting ophthalmic diseases.
- Cutting-Edge Platform: The collaboration utilizes Nona’s Harbour Mice® technology, offering fully human monoclonal and heavy chain-only antibodies.
- Transformative Potential: The Harbour Mice® HCAb platform accelerates next-generation antibody therapies with smaller, more efficient molecules.
Nona Biosciences, a global leader in biotechnology and antibody discovery, has entered into a strategic collaboration with Kodiak Sciences Inc. (Nasdaq:KOD). This partnership aims to harness Nona’s proprietary Harbour Mice® platform to develop innovative multi-target antibodies designed to treat ophthalmic diseases, a leading cause of vision loss worldwide.
Revolutionizing Antibody Development
Nona Biosciences’ Harbour Mice® platform is a state-of-the-art technology for generating fully human monoclonal antibodies. It offers two formats: the H2L2 format, consisting of two heavy and two light chains, and the HCAb format, which produces heavy chain-only antibodies.
The HCAb format is particularly transformative, creating antibodies that are approximately half the size of conventional immunoglobulins. These smaller molecules bring significant advantages, including improved therapeutic efficiency, enhanced tissue penetration, and reduced complexity in development. The platform eliminates the need for additional engineering or humanization, streamlining the process of antibody discovery.
Under the agreement, Kodiak Sciences will leverage both H2L2 and HCAb Harbour Mice® technologies for various programs focused on therapeutic antibody discovery and development. This collaboration aligns with Kodiak’s commitment to delivering next-generation retinal medicines.
About the Partners
Nona Biosciences
Nona Biosciences is at the forefront of biotechnology, offering integrated solutions from "Idea to IND" (I to ITM). Their comprehensive services cover target validation, antibody discovery, and preclinical research. Using the Harbour Mice® platforms alongside single B cell screening, Nona drives the invention of transformative antibody-based therapeutics.
The company’s Harbour Mice® technology has gained recognition for its ability to accelerate therapeutic innovations, focusing on next-generation drugs that address unmet medical needs.
Kodiak Sciences Inc.
Kodiak Sciences is a biopharmaceutical company dedicated to advancing therapies for retinal diseases. By integrating new science into drug design and manufacturing, Kodiak is developing transformative treatments for conditions such as macular degeneration and diabetic retinopathy, which are among the leading causes of blindness.
Through its collaboration with Nona Biosciences, Kodiak aims to expand its pipeline of antibody-based therapeutics, further cementing its position as a leader in retinal medicine innovation.
